XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 160 filers reported holding XENON PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.16 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $838,285 | -9.4% | 21,500 | 0.0% | 0.14% | -18.8% |
| Q1 2024 | $925,575 | -9.9% | 21,500 | 0.0% | 0.17% | -66.3% |
| Q4 2023 | $1,027,055 | +43.0% | 21,500 | 0.0% | 0.50% | +241.2% |
| Q3 2023 | $718,100 | -12.7% | 21,500 | 0.0% | 0.15% | -18.7% |
| Q2 2023 | $822,375 | -3.0% | 21,500 | 0.0% | 0.18% | -43.3% |
| Q4 2022 | $847,745 | +9.0% | 21,500 | 0.0% | 0.32% | +68.1% |
| Q3 2022 | $778,000 | +3.2% | 21,500 | -12.2% | 0.19% | +15.8% |
| Q2 2022 | $754,000 | -2.2% | 24,500 | 0.0% | 0.16% | +24.1% |
| Q4 2021 | $771,000 | +0.1% | 24,500 | 0.0% | 0.13% | -5.0% |
| Q3 2021 | $770,000 | +69.2% | 24,500 | 0.0% | 0.14% | +59.1% |
| Q2 2021 | $455,000 | +5.3% | 24,500 | 0.0% | 0.09% | -3.3% |
| Q1 2021 | $432,000 | +15.5% | 24,500 | 0.0% | 0.09% | +7.1% |
| Q4 2020 | $374,000 | +29.9% | 24,500 | 0.0% | 0.08% | +9.0% |
| Q3 2020 | $288,000 | – | 24,500 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 2,754,266 | $107,388,831 | 7.33% |
| Altium Capital Management LP | 360,600 | $14,059,794 | 5.74% |
| Affinity Asset Advisors, LLC | 994,227 | $38,764,911 | 4.47% |
| First Light Asset Management, LLC | 1,306,260 | $50,931,077 | 4.46% |
| Nan Fung Group Holdings Ltd | 106,680 | $4,159,453 | 4.44% |
| Ally Bridge Group (NY) LLC | 169,369 | $6,603,697 | 3.93% |
| TLS Advisors LLC | 32,956 | $1,285 | 3.22% |
| BRAIDWELL LP | 2,560,573 | $99,836,741 | 3.13% |
| Paradigm Biocapital Advisors LP | 2,043,280 | $79,667,487 | 3.05% |
| BRIDGER MANAGEMENT, LLC | 146,800 | $5,723,732 | 2.94% |